2024.02.26 Press Release

PassPort Technologies, Inc. Initiated US Phase I Clinical Trial of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine

PassPort Technologies, inc., one of our group companies, initiated a US Phase 1 clinical study of Zolmitriptan PassPort® utilizing its proprietary transdermal microporation system, PassPort® platform technology. The study objectives are to evaluate the safety of PassPort® system and pharmacokinetics to anticipate faster onset of action compared to zolmitriptan oral tablet.

Link to PassPort Technologies’ press release